Biotel Announces Record Revenues and Earnings for F... ( MINNEAPOLIS Sept. 30 /- Biotel In...)

Biotel Announces Record Revenues and Earnings for Fiscal 2008

Date:9/30/2008

MINNEAPOLIS, Sept. 30 /PRNewswire-FirstCall/ -- Biotel Inc. (OTC Bulletin Board: BTEL) announced results for the year ended June 30, 2008, with net earnings of $666,000, or $0.23 per diluted share, on revenues of $11,495,000. This compares to net earnings of $520,000, or $0.19 per share, on revenues of $11,233,000 for the prior year. For its fourth quarter, the company reported net earnings of $191,000, or $0.07 per diluted share, on revenues of $3,187,000. This compares to net earnings of $221,000, or $0.08 per diluted share, on revenues of $3,115,000 in the fourth quarter of 2007.
Highlights for the quarter and year are as follows:

-- Sixth year in a row of profitable growth.

-- Record sales for the fourth quarter and year

-- Net income for the year up 28.1 percent over 2007

-- Gross margin for the year was 44.4% versus 42.6% last year

"Biotel achieved a record fiscal year in revenues and earnings with a strong improvement in the fourth quarter over the third quarter," Biotel President and CEO Steve Springrose said. "Our Braemar Holter devices, event recorders, liposuction and other medical devices made strong revenue contributions, and our Agility 24/7 cardiac monitoring services continued to make very strong year over year gains. The highlight of the quarter was the introduction of our new ER920W cardiac arrhythmia monitor, our first entry into the high potential wireless market. Very importantly, we have already received FDA 510(k) approval of our next generation wireless monitor employing 'Fusion' technology, scheduled for product introduction early in calendar 2009. Biotel serves as a development partner to medical corporations seeking new devices and clinical research services."

3 months ended 3 months ended %

June 30, 2008 June 30, 2007 Change

Revenues $3,187,000 $3,115,00
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results

Post Your Comments:

Biotel Announces Record Revenues and Earnings for F...( MINNEAPOLIS Sept. 30 /- Biotel In...)